<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0507233847
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        MIRVASO 3 MG/G GEL
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BRIMONIDINE TARTRATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Topical
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Gel
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        3
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tube
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        186.75
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="GALDERMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            GALDERMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            GALDERMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        D11AX21
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Mirvazo contains the active substance brimonideine which belongs to a group of medicines commonly referred to as &quot;alpha agonists&quot;.</p><p>It is applied to the skin of the face to treat redness due to rosacea in adult patients.</p><p>Redness of the face due to rosacea is caused by high levels of blood flow in the facial skin, which is the result of enlargement (dilation) of the small blood vessels of the skin.</p><p>When applied, Mirvaso acts to narrow these blood vessels again which reduces the excess blood flow and redness.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Mirvaso:</strong></p><p>- If you allergic to brimonidine or any of the other ingredeints of this medicine (listed in section 6).</p><p>- In children below 2 years of age, who may be at greater risk of side effects from any of the medicine absorbed through the skin.</p><p>- If you are taking cetain medicines used for depression or Parkinson&#39;s disease including so-called monoamine oxidase (MAO) inhibitors (for example selegiline or moclobemide) or tricyclic antidepressants (such as imipramine) or tetracyclic antideprassants (such as maprotiline, mianserin or mirtazapin), using Mirvaso while taking these medicines may result in a fall in blood pressure.</p><p>- On irritated skin (including following laser therapy) or open wounds.</p><p><strong>Warnings and precautions</strong></p><p>Talk to your doctor, before using Mirvaso if:</p><p>- The skin of your face is irritated or has open wounds.</p><p>- You have problems with your heart or circulation.</p><p>- You have depression, decreased blood flow to the brain or the heart, fall in blood pressure on standing up, decreased blood flow to the hands, feet or skin, or Sjogren&#39;s syndrome (a chronic disease in which the body&#39;s naturak defence - the immune system - attacks the moisture-produing glands).</p><p>- You have kidney or liver problems or have had them in the past.</p><p><u>Worsening of the skin redness, flushing or burning feeling of the skin:</u></p><p>Some patients experience the return of their redness worse that it was initially.</p><p>Such worsening of redness usually develops within the first 2 weeks of treatment with Mirvaso. Generally, it resolves spotaneously after treatment is stopped.</p><p>The effect should gradually disappear within a few days in most cases. Before you restart the treatment with Mirvaso, test it on small area of the face on a day when you can stay at home. If you do not experience worsening of redness or burning, continue with the usual treatment (see section 3).</p><p>In case of worseining or unexpected redness, discontinue the treatment and contact your doctor.</p><p>If any of the above applies to you, talk to your doctor since this medicine may not be suitable for you.</p><p><strong>Children and adolescents</strong></p><p>Do not give this medicine to children and adolescents under the age of 18 years because the safety and efficacy has not been established for this age group. This is particularly important in children under the age of 2 years (see &#39;Do not use Mirvaso&#39;).</p><p><strong>Other medicines and Mirvaso</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, because these medicines could affect your treatment with Mirvaso or Mirvaso could affect your treatment with theses medicines.</p><p>Do not take Mirvaso with selegiline, moclobemide, imipramine, mianserin, or maprotiline, which are medicines that can be used for depression or Parkinson&#39;s disease, as this could lead to a change in the effectiveness of Mirvaso or could increase the chances for side effects such as a fall in blood pressure (see under &#39;Do not use Mirvaso&#39;).</p><p>Also, tell your doctor if you are taking any of the following medicines:</p><p>- Medicines used for the treatment of pain, sleep disorders, or anxiety disorder.</p><p>- Medicines used for the treatment of psychiatric disorders (chlorpromazine) or used for hyperactivity (methylphrnidate) or used for high blood pressure (reserpine).</p><p>- Medicines which act on the same body mechanism as Mirvaso (othe alphaagonists, e.g. clonidine; so-called alpha blockers or alpha antagonists, e.g. prazosin, isoprenaline which are most often used for treatment of high blood pressure, slow heart rate of asthma).</p><p>- Cardiac glycosides (e.g. digoxin), used to treat heart problems.</p><p>- Blood pressure lowering medicine such as bete-blockers or calcium channel blockers (e.g. propoanolol, amlodipine).</p><p>If any of the above applies to you, or if you are unsure, talk to your doctor.</p><p><strong>Mirvaso with alcohol</strong></p><p>Tell your doctor if you consume alcohol regularly as this could affect your treatment with this medicine.</p><p><strong>pregnancy and breast-feeding</strong></p><p>The use of Mirvaso is not recommended during pregnancy. This is because it&#39;s effects on your unborn baby are unknown. You should not use this medicine during breast-feeding.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before using this medicine.</p><p><strong>Driving and using machines</strong></p><p>Mirvaso has no significant influence on the ability to drive and use machines.</p><p><strong>Mirvaso contains:</strong></p><p>- Methylparahydroxybenzoate which may cause allergic reactions (possibly delayed).</p><p>- Propylene glycol which may cause skin irritation.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always use this medicines exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><u><strong>Important: </strong></u>Mirvaso is intended for adults and only for use on the skin of the face. Do not use this medicine on other parts of your body, especially moist body surfaces, e.g. your eyes, mouth, nose or vagina.</p><p>Do not swallow.</p><p>Keep Mirvaso gel away from children.</p><p>Mirvaso is recommended to be applied to the face once a day only.</p><p>A small pea size amount of gel should be applied to the forehead, chin, nose and each cheek, and spread smoothly and evenly as a thin layer across the area. Do not exceed the total daily recommended dose (5 pea size amounts). You must avoid the eyes, eyelids, lips, mouth and the inside of the nose. Should any gel get onto those areas, wash them immediately with plenty of water. If you experience worsening of redness or burning you should stop using Mirvaso and contact your doctor if needed.</p><p>Do not apply any other skin medicines or cosmetics immedaitely before the daily application of Mirvaso. You should use these products only after the applied Mirvaso has dried. You should wash your hands immediately after applying this medicine.</p><p><strong>How to open the tube with a child-resistant cap</strong></p><p>To avoid spilling, do not squeeze the tube while opening or closing.</p><p>Push down on the cap and turn counterclockwise (turn to the left). Then pull the cap off.</p><p><img alt="" width="209" height="101" src="data:image/png;base64,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" /></p><p><strong>How to close the tube with a child-resistant cap</strong></p><p>Push down and turn clockwise (turn to the right).</p><p><img alt="" width="106" height="92" src="data:image/png;base64,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" /></p><p><strong>If you use more Mirvaso than you sould</strong></p><p>If you use more than the daily recommneded dose within a 24 hour period, it could lead to skin irritation or other side effects at the application site. Repeated doses within the same 24 hour period could result in side effects, such as low blood pressure, drowsiness or sleepiness.</p><p>Please contact your doctor, who will avise you on what action to take.</p><p><strong>If anyone, especailly a child, accidentally swallows Mirvaso, they may have serious side effects and need to be treated in a hospital.</strong></p><p>Contact your doctor immediately or go to a hospital emergency department right away if you, a child, or anyone else swallows this medicine and has any of these symptoms: feeling dizzy from low blood pressure, vomiting, tiredness or drowsiness, decreased or irregular heartbeats, small pupils (constricted pupils), difficult or slow breathing, floppiness, low body temperature and convulsions (fits). Take the medicine pack with you, so the doctor knows what was swallowed.</p><p><strong>If you forget to use Mirvaso</strong></p><p>Mirvaso works on a daily basis, starting with the first day of treatment. If you miss a daily dose, your redness will not be reduced for that day. Do not use a double dose to make up for a forgotten dose.</p><p><strong>If you stop using Mirvaso</strong></p><p>Please contact your doctor before stopping your treatment.</p><p>If you have any further questons on the use if this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.&nbsp;</p><p>If you develope severe irritation or contact allergy (e.g. allergic reaction, rash), uncommon side effects, stop using Mirvaso and see your doctor. In some cases, symptopms may extend beyond the treatment area.</p><p>Mirvaso may also cause the following other side effects:</p><p>Common side effects (may affect up to 1 in 10 people):</p><p>- Flushing.</p><p>- Excessive whitening (pollar) where the gel is applied.</p><p>- Worsening of rosecea.</p><p>- Skin redness, burning feeling of the skin or itching.</p><p>Uncommon side effects (may affect up to 1 in 100 people):</p><p>- Acne.</p><p>- Dry mouth.</p><p>- Feeling cold in hands and feet.</p><p>- Feeling hot.</p><p>- Headache.</p><p>- Nasal congestion.</p><p>- Skin rash, skin pain, or discomfort, skin irritation or inflammation, dry skin, warm skin sensation, tingling or sensation of pins and needles.</p><p>- Swelling of the eyelid.</p><p>- Swelling of the face.</p><p>- Urticaria.</p><p>- Dizziness.</p><p>Rare side effects (may affect up to 1 in 1000 people):</p><p>- Angioedema (a serious allergic reaction usually with swelling of the face, mouth or tongue). Stop treatment if this occurs.</p><p>- Hypotension (blood pressure decreased), dizziness.</p><p>- Heart rate decrease (slow heart rate, known as bradycardia).</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects, you can help provide more information on the safety of this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Store this medicine below 30C.</p><p>Do not freeze.</p><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date refers to the last day of that month.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substanc is brimonidine. One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mh of brimonidine tartrate.</p><p>- The other ingredients are carbomer, methylparahydroxybenzoate (E218), phenoxyethanol, glycerol, titanium dioxide, propylene glycol, sodium hydroxide, purified water. See end of section 2 for information on methylparahydroxybezoate and propylene glycol.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Mirvaso is a white to light yellow, opaque gel. It is supplied in tubes containing 2, 10, or 30 grams of gel. Pack size of 1 tube.
Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><u>Marketing Authorization Holder</u></p><p>Galderma International</p><p>Tour Europlaza, 20 avenue Andre Prothin - La Defense 4</p><p>La Defense Cedex 92927 - France</p><p><u>Manufacturer</u></p><p>Laboratoires Galderma - Z.I. Montdesir - 74540 Alby-sur-Cheran - France</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                12/2019
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي عقار ميرفاسو على المادة الفعالة بريمونيدين التي تنتمي لمجموعة من الأدوية يشار إليها عموما بإسم &quot;ناهضات ألفا&quot;.</p><p>تستخدم هذه المادة على بشرة الوجه، لعلاج الاحمرار الناجم عن الوردية في المرضى البالغين.</p><p>ينتج احمرار الوجه الناجم عن الوردية عن ارتفاع مستويات تدفق الدم في بشرة الوجه، وهو ما ينتج عن تضخم (توسع) الأوعية الدموية الدقيقة في البشرة.</p><p>يعمل عقار ميرفاسو عند استخدامه على تضييق هذه الأوعية الدموية مجددا، وهو ما يقلل تدفق الدم المفرط والاحمرار.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- إذا كنت تعاني من حساسية اتجاه بريمونيدين أو اتجاه أي مكون من المكونات الأخرى بهذا الداء (المدرجة في قسم:6).</p><p>- في حالة الأطفال الذين تقل أعمارهم عن عامين ممن قد يكونوا أكثر عرضة للإصابة بالآثار الجانبية من أي كمية يمتصها الجلد من الدواء.</p><p>- إذا كنت تتناول بعض الادوية التي تستخدم في علاج الإكتئاب أو مرض شلل الرعاش (مرض باركنسون) بما في ذلك مثبطات اكسيداز أحادي الأمين (على سبيل المثال: سيليجيلين أو موكلوبيميد)، أو مضادات الاكتئاب ثلاثية الحلقات (مثل ايميبرامين)، أو مضادات الاكتئاب رباعية الحلقات (مثل مابروتيلن، ميانسيرين أو ميرتازابين)، قد يؤدي استخدام عقار ميرفاسو عند تناول هذه الأدوية الى انخفاض ضغط الدم.</p><p>- على الجلد المتهيج (ويشمل ما بعد العلاج بالليزر) أو الجروح المفتوحة.</p><p><strong>تحذيرات واحتياطات</strong></p><p>تحدث إلى طبيبك قبل تناول عقار ميرفاسو في الحالات التالية:</p><p>- إذا اصبت بتهيج ببشرة الوجه، أو كانت به جروح مفتوحة.</p><p>- إذا كنت تعاني من مشاكل بالقلب أو بالدورة الدموية.</p><p>- إذا كنت تعاني من الإكتئاب، انخفاض تدفق الدم إلى المخ أو القلب، أو انخفاض ضغط الدم عند النهوض، أو انخفاض تدفق الدم الى اليدين أو القدمين أو الجلد، أو إذا كنت مصابا بمتلازمة شوغرن (مرض مزمن تهاجم به آلية الجسم الدفاعية -الجهاز المناعي- الغدد المنتجة للرطوبة).</p><p>- إذا كانت لديك مشاكل بالكلى أو الكبد أو إذا اصبت بها من قبل.</p><p><u>تفاقم إحمرار الجلد أو تورده أو الشعور بحرق الجلد:</u></p><p>قد يعاود بعض المرضى الاحمرار على نحو اسوأ مما كان في بدايته. يتفاقم هذا الاحمرار عادة في غضون اول اسبوعين من العلاج بعقار ميرفاسو، وعادة ما يختفي الإحمرار تلقائيا بعد وقف العلاج. يفترض أن يختفي تأثير العقار تدريجيا في غضون أيام قليلة في أغلب الحالات. قبل إعادة بدء العلاج بعقار ميرفاسو، اختبره على منطقة صغيرة من الوجه في يوم يمكنك البقاء بالمنزل فيه. إذا لم يتفاقم الاحمرار أو حرقة الجلد لديك، فتابع العلاج المعتاد (انظر قسم:3)</p><p>في حالة تفاقم احمرار الجلد أو الاصابة على نحو غير متوقع، قم بوقف العلاج واتصل بطبيبك.</p><p>إذا كان أي مما سبق أعلاه ينطبق عليك، فتحدث إلى طبيبك، إذ قد يكون هذا الدواء غير مناسب لك.</p><p><strong>الاطفال والمراهقون</strong></p><p>لا تعط هذا الدواء للأطفال والمراهقين الذين تقل أعمارهم عن 18 عاما، إذ لم يثبت امانه وفعاليته لهذه الفئة العمرية. هذا مهم بوجه خاص في الأطفال الذين تقل أعمارهم عن عامين (انظر &quot;لا تستخدم عقار ميرفاسو في الحالات التالية&quot;).</p><p><strong>استخدام عقار ميرفاسو مع أدوية أخرى</strong></p><p>أخبر طبيبك أو الصيدلي الخاص بك إذا كنت تتناول، أو تناولت مؤخرا، أو قد تتناول أي أدوية أخرى، لأن هذه الأدوية قد تؤثر على علاجك بعقار ميرفاسو، أو لأن عقار ميرفاسو قد يؤثر على علاجك بهذه الأدوية.</p><p>لا تستخدم عقار ميرفاسو مع سيليجيلين أو موكلوبيميد أو إيميبرامين أو ميانسيرين أو مابروتيلين وهي أدوية يمكن استخدامها لعلاج الإكتئاب أو مرض الشلل الرعاش (باركنسون)، لأن هذا قد يؤدي إلى تغيير فعالية عقار ميرفاسو أو قد يرفع فرص إصابتك بالآثار الجانبية له مثل: انخفاض ضغط الدم الشديد (انظر ادناه &quot;لا تستخدم عقار ميرفاسو في الحالات التالية&quot;).</p><p>أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية:</p><p>- الأدوية التي تستخدم لعلاج الألم، أو اضطرابات النوم أو اضطرابات القلق.</p><p>- الأدوية التي تستخدم لعلاج الإضطرابات النفسية (كلوربرومازين)، أو التي تستخدم لعلاج فرط النشاط (ميثيل فينيديت)، أو التي تستخدم لعلاج ارتفاع ضغط الدم (ريسيربين).</p><p>- الادوية التي تعمل على نفس آلية الجسم التي يستخدمها عقار ميرفاسو (ناهضات ألفا الأخرى، مثل: كلونيدين، وما يسمى بحاصرات الفا او مناهضات الفا، مثل: برازوسين، وأيزوبرينالين، التي تستخدم غالبا لعلاج ارتفاع ضغط الدم، بطء ضربات القلب أو الربو).</p><p>- جليكوسيدات القلب: (مثل ديجوكسين) المستخدم في علاج مشكلة القلب.</p><p>- الادوية الخافضة لضغط الدم مثل: حاصرات بيتا أو حاصرات قنوات الكالسيوم (على سبيل المثال: بروبرانولول، أملوديبين).</p><p>إذا كان أي مما سبق ينطبق عليك أو إذا لم تكن متأكدا، تحدث إلى طبيبك.</p><p><strong>عقار ميرفاسو مع الكحوليات</strong></p><p>اخبر طبيبك إذا كنت تتناول الكحوليات بإنتظام، إذ قد يؤثر هذا في علاجك بهذا الدواء.</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>لا يوصى باستخدام عقار ميرفاسو أثناء الحمل. هذا لأن تأثيراته على جنينك غير معروفة. يجب عليك عدم استخدام هذا الدواء أثناء ممارسة الرضاعة.</p><p>إذا كنت حاملا أو مرضعا، أو تعتقدين أنك حامل أو تخططين لذلك، فاستشيري طبيبك قبل تناول هذا الدواء.</p><p><strong>القيادة واستخدام الالات</strong></p><p>لا يوجد تأثير لعقار ميرفاسو في القدرة على القيادة واستخدام الالات.</p><p><strong>يحتوي عقار ميرفاسو على:</strong></p><p><strong>- ميثيل الباراهيدروكسي بنزوات</strong> الذي قد يسبب تفاعلات حساسية (قد تتأخر).</p><p><strong>- بروبيلين الجليكول</strong> الذي قد يسبب تهيج البشرة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>استخدم دائما هذا الدواء كما أخبرك طبيبك بالضبط، يرجى مراجعة الطبيب أو الصيدلي إذا لم تكن متأكدا من كيفية التناول.</p><p><strong>هام:</strong> عقار ميرفاسو مخصص للبالغين ولا يستخدم إلى على بشرة الوجه. لا تستخدم هذا الدواء على أجزاء أخرى من الجسم، لا سيما أسطح الجسم الرطبة، على سبيل المثال: العينين، أو الفم أو الأنف أو المهبل.&nbsp;</p><p>لا تبلعها.</p><p>احفظ عقار ميرفاسو جل بعيدا عن متناول الأطفال.</p><p>يوصى باستخدام عقار ميرفاسو على الوجه مرة واحدة فقط يوميا.</p><p>يجب وضع كمية من الجل بحجم حبة البازلاء على جبهة الوجه، الذقن، الأنف، وكلا الوجنتين، ثم قم بتوزيعها بلطف وبالتساوي في هيئة طبقة رقيقة على هذه المناطق كلها. لا تستخدم كمية أكبر من الجرعة اليومية الموصى بها (مقدار 5 حبات بازلاء). يجب عليك تجنب ملامسة الجل للعينين، وللجفنين، وللشفتين، وللفم، وداخل الأنف. إذا بلغت أي كمية من الجل هذه المناطق، قم بغسل المنطقة فورا بالكثير من الماء. إذا تفاقم احمرار الجلد أو الحرق لديك، يجب عليك التوقف عن استخدام عقار ميرفاسو والاتصال بطبيبك إذا لزم الأمر.</p><p>لا تستخدم أي أدوية جلدية أخرى أو مستحضرات تجميل قبل الاستخدام اليومي لعقار ميرفاسو مباشرة.</p><p>يجب عليك عدم استخدام هذه المنتجات إلا بعد أن تجف الكمية التي وضعتها من عقار ميرفاسو.</p><p>يجب عليك غسل يديك مباشرة بعد استخدام هذا الدواء.</p><p><strong>كيفية فتح انبوب العقار المزود بغطاء مقاوم للأطفال</strong></p><p>لتجنب انسكاب العقار، لا تضغط على الأنبوب أثناء فتحه أو غلقه.</p><p>ادفع الغطاء لأسفل أو دره عكس اتجاه عقارب الساعة (أدره إلى اليسار). ثم انزع غطاء الأنبوب.</p><p><img alt="" width="209" height="101" src="data:image/png;base64,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" /></p><p>كيفية إغلاق أنبوب العقار المزود بغطاء مقاوم للأطفال</p><p>ادفع الغطاء لأسفل وأدره في اتجاه عقارب الساعة (ادره إلى اليمين).</p><p><img alt="" width="106" height="92" src="data:image/png;base64,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" /></p><p><strong>إذا استخدمت كمية أكثر مما يجب من عقار ميرفاسو</strong></p><p>إذا استخدمت كمية أكثر من الجرعة اليومية الموصى بها في غضون 24 ساعة، فقد يؤدي هذا إلى تهيج الجلد أو الإصابة بآثار جانبية أخرى بموضع استعمال العقار. قد يؤدي تكرار الجرعة في غضون 24 ساعة إلى تأثيرات جانبية مثل: انخفاض ضغط الدم، الدوار أو النعاس.</p><p>يرجى الاتصال بطبيبك الذي سينصحك بما عليك القيام به.</p><p><strong>إذا ابتلع أي شخص -لا سيما الأطفال- عن طريق الخطأ عقار ميرفاسو، فقد يصاب بتأثيرات جانبية خطيرة، ويحتاج إلى العلاج بالمستشفى.</strong></p><p>اتصل بطبيبك فورا أو توجه لقسم الطواريء بأحد المستشفيات فورا إذا ابتعلت أو ابتلع طفل أو أي شخص آخر هذا الدواء وأصيب بأي من الأعراض التالية: شعور بدوخة بسبب انخفاض ضغط الدم، قيء، أو بطء التنفس، أو إخفاق وإنخفاض حرارة الجسم والتشنجات (النوبات). اصطحب معك عبوة الدواء، ليعرف طبيبك ما الذي تم ابتلاعه.</p><p><strong>إذا أغفلت تناول عقار ميرفاسو</strong></p><p>يعمل عقار ميرفاسو بشكل يومي، بدءا من اليوم الأول من العلاج. إذا نسيت جرعة يومية، لن يقلل الاحمرار لديك لهذا اليوم. لا تستخدم جرعة مضاعفة لتعويض الجرعة التي أغفلتها.</p><p><strong>إذا توقفت عن تناول عقار ميرفاسو</strong></p><p>يرجى الاتصال بطبيبك قبل وقف العلاج.</p><p>إذا كانت لديك أية اسئلة اضافية حول استخدام هذا الدواء، فأستشر الطبيب أو الصيدلي الخاص بك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثله مثل كافة الأدوية، قد يسبب هذا الدواء آثارا جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p>إذا اصبت بتهيج شديد، أو إذا أصبت بحساسية التماسية (على سبيل المثال: تفاعلات حساسية، طفح جلدي)، آثار جانبية غير شائعة، توقف عن تناول عقار ميرفاسو وراجع طبيبك. في بعض الحالات، قد تمتد الأعراض لتصيب مناطق أخرى بخلاف منطقة العلاج.</p><p>قد يسبب عقار ميرفاسو أيضا الآثار الجانبية التالية:</p><p>الآثار الجانبية الشائعة (قد تؤثر في ما يصل إلى 1 من كل 10 أشخاص):</p><p>- تورد الجلد.</p><p>- بياض مفرط عند وضع الجل على الجلد.</p><p>- تفاقم الوردية.</p><p>- احمرار الجلد، شعور بحرقة بالجلد أو بحكة.</p><p>الآثار الجانبية المحتملة غير الشائعة: (قد تؤثر على ما يصل إلى 1 من بين كل 100 شخص) تشمل:</p><p>- حب الشباب.</p><p>- جفاف الفم.</p><p>- شعور ببرودة في اليدين والقدمين.</p><p>- شعور بالحر.</p><p>- صداع.</p><p>- احتقان الأنف.</p><p>- طفح جلدي، ألم أو شعور بضيق بالبشرة، تهيج البشرة أو التهابها، جفاف البشرة، شعور بحرارة بالبشرة، تنميل أو شعور بوخز كوخز الإبر والمسامير.</p><p>- تورم الجفنين.</p><p>- تورم الوجه.</p><p>- ارتكاريا.</p><p>- دوخة.</p><p>الآثار الجانبية النادرة (قد تؤثر في ما يصل إلى 1 من كل 1000 شخص):</p><p>- وذمة وعائية (تفاعل حساسية خطير مصحوب عادة بتورم في الوجه أو الفم أو اللسان). توقف عن تناول العلاج إذا حدث هذا.</p><p>- انخفاض ضغط الدم، دوخة.</p><p>- انخفاض معدل ضربات القلب.</p><p><strong>الإبلاغ عن الآثار الجانبية</strong></p><p>إذا ظهرت لديك أية آثار جانبية، فتحدث إلى طبيبك. بما في ذلك أية آثار جانبية محتملة، غير المدرجة في هذه النشرة بالابلاغ عن الآثار الجانبية، يمكنك المساعدة في تقديم المزيد من المعلومات حول أمان هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>لا تعرضه للتجميد.</p><p>&nbsp;يحفظ هذا الدواء بعيدا عن رؤية ومتناول الأطفال.</p><p>لا تستعمل هذا الدواء بعد تاريخ انتهاء الصلاحية المدون على العبوة والأنبوب بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية الى اليوم الأخير من ذلك الشهر.</p><p>لا تتخلص من الأدوية عن طريق إلقائها في مياه الصرف أو مع المخلفات المنزلية. استشر الصيدلي الخاص بك عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد تلك الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- المادة الفعالة هي بريمونيدين. يحتوي كل جرام من الجل على 3.3مجم من بريمونيدين، أو ما يعادل 5مجم من تارترات البريمونيدين.</p><p>- المواد الفعالة الأخرى هي: كربومير، ميثيل الباراهيدروكسي بنزوات (E218)، فينوكسي ايثانول، جليسرول، ثاني اكسيد التيتانيوم، بروبيلين الجليكول، هيدروكسيد الصوديوم، ماء منقى. انظر نهاية قسم 2 لمزيد من المعلومات عن ميثيل الباراهيدروكسي بنزوات وبروبيلين الجليكول.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>عقار ميرفاسو هو جل غير شفاف ذو لون أبيض مائل إلى الأصفر الفاتح. يتوفر في أنابيب تحتوي على 2 أو 10 أو 30جرام من الجل.</p><p>قد لا يتم تسويق جميع أحجام العبوات.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><u>مالك حق التسويق</u></p><p>شركة جالديرما إنترناشيونال</p><p>برج يوروبلازا، 20 شارع أندريه بروثين - لا ديفانس 4</p><p>لا ديفانس سيدكس 92927</p><p>فرنسا</p><p><u>جهة التصنيع</u></p><p>معامل جالديرما</p><p>زد.إي.مونتديزير</p><p>74540 ألبي-سير-شيران.</p><p>فرنسا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            12/2019
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mirvaso 3 mg/g gel
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One gram of gel contains 3.3 mg of brimonidine, equivalent to 5 mg of brimonidine tartrate.
Excipient(s) with known effect:
One gram of gel contains 1 mg methylparahydroxybenzoate (E218) and 55 mg propylene glycol.
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Gel.
White to light yellow opaque aqueous gel.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirvaso is indicated for the symptomatic treatment of facial erythema of rosacea in adult patients.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>One application per&nbsp;24&nbsp;hours, at any time suitable for the patient, for as long as facial erythema is present.</p><p>The maximum daily recommended dose is&nbsp;1&nbsp;g of gel in total weight, which corresponds to approximately five pea sized amounts.</p><p>Treatment should be initiated with a smaller amount of gel (less than the maximum) for at least one week. The amount of gel can then be increased gradually based on tolerability and patient response.</p><p><em><u>Special populations</u></em></p><p><em>Elderly patients</em></p><p>The experience of use of Mirvaso in patients aged above&nbsp;65&nbsp;years is limited (see also section&nbsp;4.8).</p><p><em><u>Paediatric population</u></em></p><p>The safety and efficacy of Mirvaso in children and adolescents aged less than&nbsp;18&nbsp;years have not been established. No data are available.</p><p>Mirvaso is contraindicated in children aged less than&nbsp;2&nbsp;years because of serious systemic safety risk (see section&nbsp;4.3). Safety concerns related to the systemic absorption of brimonidine have also been identified for the age group&nbsp;2&nbsp;to&nbsp;12&nbsp;years (see section&nbsp;4.9). Mirvaso should not be used in children or adolescents aged&nbsp;2&nbsp;to&nbsp;18&nbsp;years.</p><p><u>Method of administration</u></p><p>Cutaneous use only.</p><p>Mirvaso should be applied smoothly and evenly as a thin layer across the entire face (forehead, chin, nose and both cheeks) avoiding the eyes, eyelids, lips, mouth and membrane of the inner nose. Mirvaso should be applied only to the face.</p><p>Hands should be washed immediately after applying the medicinal product.</p><p>Mirvaso can be used in conjunction with other cutaneous medicinal products for the treatment of&nbsp;inflammatory lesions of rosacea and with cosmetics. These products should not be applied immediately before the daily application of Mirvaso; they may be used only after the applied Mirvaso&nbsp;has dried.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Children aged less than 2 years.
Patients receiving monoamine oxidase (MAO) inhibitor therapy (for example selegiline or moclobemide) and patients on tricyclic (such as imipramine) or tetracyclic (such as maprotiline, mianserin or mirtazapin) antidepressants which affect noradrenergic transmission.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirvaso should not be applied on irritated skin (including following laser therapy) or open wounds.</p><p>In case of severe irritation or contact allergy, the treatment with the medicinal product should be discontinued.</p><p>Exacerbation of rosacea symptoms is very common in patients treated with Mirvaso. Across all clinical studies, 16% of patients receiving Mirvaso experienced an event of symptom exacerbation. Treatment should be initiated with a small amount of gel and the dose increased gradually, based on tolerability and response to treatment (see section&nbsp;4.2).</p><p><u>Erythema and Flushing</u></p><p>The effect of Mirvaso topical gel begins to diminish hours after application. In some patients, erythema and flushing were reported to return with greater severity than was present at baseline. Most of the cases were observed within the first&nbsp;2&nbsp;weeks of starting the treatment (see section&nbsp;4.8).</p><p>The onset of flushing relative to application of Mirvaso topical gel varied, ranging from approximately&nbsp;30&nbsp;minutes to several hours (see section&nbsp;4.8).</p><p>In the majority of these cases, erythema and flushing resolved after discontinuation of Mirvaso&nbsp;topical&nbsp;gel.</p><p>In case worsening of erythema occurs, Mirvaso topical gel should be discontinued. Symptomatic measures, such as cooling, NSAID and antihistamines, may help in alleviating symptoms.</p><p>Recurrences of aggravated erythema and flushing have been reported after re‑administration of Mirvaso topical gel. Prior to resuming treatment after temporary discontinuation due to aggravated erythema or flushing, perform a test application on a small area of the face for at least one day before full facial application is resumed.</p><p>It is important to inform the patient not to exceed the recommended maximum dose (5&nbsp;pea size amounts) and frequency of application (once daily).</p><p>Mirvaso should not be applied close to the eyes.</p><p>Mirvaso has not been studied in patients with renal or hepatic impairment.</p><p>Any increase in the daily amount applied above 5 pea sized amounts and/or increase in frequency of daily application of the medicinal product should be avoided, since the safety of higher daily doses or repeated daily application has not been assessed.</p><p>The concomitant use of other systemic alpha adrenergic receptor agonists may potentiate the undesirable effects of this class of medicinal products in patients:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with severe or unstable or uncontrolled cardiovascular disease;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; with depression, cerebral or coronary insufficiency, Raynaud&rsquo;s phenomenon, orthostatic hypotension, thrombangiitis obliterans, scleroderma, or Sj&ouml;gren&rsquo;s syndrome.</p><p>The medicinal product contains methylparahydroxybenzoate (E218) which may cause allergic reactions (possibly delayed), and propylene glycol which may cause skin irritation.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No interaction studies have been performed.</p><p>Mirvaso is contraindicated in patients receiving monoamine oxidase (MAO) inhibitor therapy and&nbsp;patients on tricyclic or tetracyclic antidepressants which affect noradrenergic transmission (see&nbsp;section&nbsp;4.3).</p><p>The possibility of an additive or potentiating effect with central nervous system depressants (alcohol,&nbsp;barbiturates, opiates, sedatives, or anaesthetics) should be considered.</p><p>No data on the level of circulating catecholamines after Mirvaso administration are available. Caution, however, is advised in patients taking substances which can affect the metabolism and uptake of circulating amines e.g. chlorpromazine, methylphenidate, reserpine.</p><p>Caution is advised when initiating (or changing the dose of) a concomitant systemic substance (irrespective of pharmaceutical form) which may interact with alpha adrenergic receptor agonists or interfere with their activity i.e. agonists or antagonists of the adrenergic receptor e.g. (isoprenaline, prazosin).</p><p>Brimonidine may cause clinically insignificant decreases in blood pressure in some patients. Caution is therefore advised when using medicinal products such as anti‑hypertensives and/or cardiac glycosides concomitantly with brimonidine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited amount of data from the use of brimonidine in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see&nbsp;section&nbsp;5.3). As a precautionary measure, it is preferable to avoid the use of Mirvaso during pregnancy.</p><p><u>Breast‑feeding</u></p><p>It is unknown whether brimonidine/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Mirvaso should not be used during breast‑feeding.</p><p><u>Fertility</u></p><p>Brimonidine did not present any special reproductive or developmental hazard in animal species.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Mirvaso has no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly reported adverse reactions are erythema, pruritus, flushing and skin burning sensation, all occurring in&nbsp;1.2&nbsp;to&nbsp;3.3% of patients in clinical studies. They are typically mild to moderate in severity, and usually do not require discontinuation of treatment. No meaningful differences in the safety profiles were observed between the elderly subject population and subjects&nbsp;18&nbsp;to&nbsp;65&nbsp;years of age. Aggravated erythema, flushing and skin burning sensation have been reported during the post‑marketing period (see section&nbsp;4.4).</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions are classified by System Organ Class and frequency, using the following convention: very common (&ge;&nbsp;1/10), common (&ge;&nbsp;1/100&nbsp;to &lt;&nbsp;1/10), uncommon (&ge;&nbsp;1/1,000&nbsp;to &lt;&nbsp;1/100), rare (&ge;&nbsp;1/10,000&nbsp;to &lt;1/1,000), very rare (&lt;&nbsp;1/10,000), not known (cannot be estimated from the available data) and were reported with Mirvaso in clinical studies (see Table&nbsp;1).</p><p><strong>Table 1 - Adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><thead><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Bradycardia*</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Headache, paraesthesia</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Eyelid oedema</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing, pallor at the application site*</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dizziness*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Hypotension*</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Nasal congestion</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Dry mouth</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erythema, pruritus, rosacea, skin burning sensation</p></td></tr><tr><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Acne, allergic contact dermatitis, contact dermatitis, dermatitis, dry skin, pain of skin, skin discomfort, rash papular, skin irritation, skin warm, swelling face*, urticaria*</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Angioedema*</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Feeling hot, peripheral coldness</p></td></tr></tbody></table><p>* Adverse reactions reported from post‑marketing data.</p><p><u>Description of selected adverse reactions</u></p><p>Bradycardia and hypotension</p><p>Post-marketing cases of bradycardia, hypotension (including orthostatic hypotension) and dizziness have been reported, some of which required hospitalization. Some cases involved application of Mirvaso following laser procedures (see section 4.4).</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It&nbsp;allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p><strong>To report side effects:-</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p>The National Pharmacovigilance Centre (NPC):</p><p>- Fax: +966-11-205-7662</p><p>- Call NPC at +966-11-2038222, Ext: 2317-2356-2340</p><p>- SFDA Call Center: 19999</p><p>- E-mail: npc.drug@sfda.gov.sa</p><p>- Website: https://ade.sfda.gov.sa/</p><p>For other countries, you can report any side effects by<strong> </strong>contacting your health authority or you can write to us on:</p><p>&nbsp;ME.Pharmacovigilance.AEDXB@galderma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdoses after oral use of other alpha<sub>2</sub>‑agonists have been reported to cause symptoms such as hypotension, asthenia, vomiting, lethargy, sedation, bradycardia, arrhythmias, miosis, apnoea, hypotonia, hypothermia, respiratory depression and seizure.</p><p>Treatment of an oral overdose includes supportive and symptomatic therapy; a patent airway should be&nbsp;maintained.</p><p>No cases of overdose after cutaneous use of Mirvaso were reported during the clinical development program.</p><p><u>Paediatric population</u></p><p>Serious adverse reactions following inadvertent ingestion of Mirvaso by two young children of one clinical study subject have been reported. The children experienced symptoms consistent with previously reported oral overdoses of alpha<sub>2</sub>‑agonist in young children. Both children were reported to&nbsp;have made a full recovery within&nbsp;24&nbsp;hours.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other dermatological preparations, Other dermatologicals,<br />ATC code: D11AX21.</p><p><u>Mechanism of action</u></p><p>Brimonidine is a highly selective alpha<sub>2</sub>‑adrenergic receptor agonist that is&nbsp;1000‑fold more selective for the alpha<sub>2</sub>‑adrenergic receptor than the alpha<sub>1</sub>‑adrenergic receptor.</p><p><u>Pharmacodynamic effects</u></p><p>Cutaneous facial application of a highly selective alpha<sub>2</sub>‑adrenergic receptor agonist reduces erythema through direct cutaneous vasoconstriction.</p><p><u>Clinical efficacy and safety</u></p><p>The efficacy of Mirvaso in the treatment of moderate to severe facial erythema of rosacea has been demonstrated in two randomised, vehicle controlled blinded clinical trials, which were identical in design. Moderate to severe erythema was defined as a grade&nbsp;3&nbsp;or greater on both the Clinician Erythema Assessment (CEA) scale and Patient Self‑Assessment (PSA) scale. The studies were conducted in&nbsp;553&nbsp;randomised subjects aged&nbsp;18&nbsp;years and older who were treated once daily for&nbsp;4&nbsp;weeks with either Mirvaso or vehicle. Of these,&nbsp;539&nbsp;completed&nbsp;29&nbsp;days of treatment and had data available to be included in the efficacy analysis at Day&nbsp;29, with the majority being Caucasians between&nbsp;18&nbsp;and&nbsp;65&nbsp;years of age.</p><p>The primary endpoint was expressed in terms of composite success i.e. subjects responding with a&nbsp;2‑grade reduction on both baseline CEA score and baseline PSA score on Day&nbsp;29. The results from both clinical studies demonstrated that Mirvaso was significantly more effective (p&lt;0.001) in the reduction of facial erythema of rosacea than vehicle gel when applied once daily for&nbsp;29&nbsp;days (primary endpoint, see Table&nbsp;2). For the population subset of patients with severe erythema at baseline Day&nbsp;1&nbsp;(i.e. subjects with CEA or PSA grade of&nbsp;4) which represented&nbsp;26% of the randomised subjects, the results on the primary endpoint on Day&nbsp;29&nbsp;were similar to those results observed in the overall population (see Table&nbsp;3) and were statistically significant for both studies combined (p=0.003). In addition, for the overall population, Mirvaso demonstrated statistical superiority (p&lt;0.001) over vehicle gel with respect to rapid initial onset of a clinically meaningful effect (1‑Grade Composite Success for CEA and PSA) after the first application at&nbsp;30&nbsp;minutes on Day&nbsp;1(secondary endpoint&nbsp;27.9% vs.&nbsp;6.9% for Study&nbsp;1,&nbsp;28.4% vs.&nbsp;4.8% for Study&nbsp;2), and to achievement of a clinically meaningful effect (1‑Grade Composite Success for CEA and PSA) on Day&nbsp;29&nbsp;(tertiary endpoint, see Table&nbsp;4).</p><p>CEA and PSA were defined as follows:</p><p>CEA: Clinician Erythema Assessment:&nbsp;0=Clear skin with no signs of erythema,&nbsp;1=Almost clear; slight redness,&nbsp;2=Mild erythema; definite redness,&nbsp;3=Moderate erythema+ marked redness and&nbsp;4=Severe erythema+ fiery redness</p><p>PSA: Patient Self‑Assessment:&nbsp;0=No redness,&nbsp;1=Very mild redness,&nbsp;2=Mild redness,&nbsp;3=Moderate redness and&nbsp;4=Severe redness</p><p><strong>Table&nbsp;2: Percentage of subjects with a&nbsp;2‑grade improvement in both </strong><strong>CEA and PSA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:619px"><thead><tr><td rowspan="2" style="vertical-align:top"><p>Success day&nbsp;29</p></td><td colspan="2" style="vertical-align:top"><p>Study&nbsp;1</p></td><td colspan="2" style="vertical-align:top"><p>Study&nbsp;2</p></td></tr><tr><td style="vertical-align:top"><p>Mirvaso Gel&nbsp;n=127</p></td><td style="vertical-align:top"><p>Vehicle Gel&nbsp;n=128</p></td><td style="vertical-align:top"><p>Mirvaso Gel&nbsp;n=142</p></td><td style="vertical-align:top"><p>Vehicle Gel&nbsp;n=142</p></td></tr></thead><tbody><tr><td style="vertical-align:top"><p>3&nbsp;hours after application</p></td><td style="vertical-align:top"><p>31.5%</p></td><td style="vertical-align:top"><p>10.9%</p></td><td style="vertical-align:top"><p>25.4%</p></td><td style="vertical-align:top"><p>9.2%</p></td></tr><tr><td style="vertical-align:top"><p>6&nbsp;hours after application</p></td><td style="vertical-align:top"><p>30.7%</p></td><td style="vertical-align:top"><p>9.4%</p></td><td style="vertical-align:top"><p>25.4%</p></td><td style="vertical-align:top"><p>9.2%</p></td></tr><tr><td style="vertical-align:top"><p>9&nbsp;hours after application</p></td><td style="vertical-align:top"><p>26.0%</p></td><td style="vertical-align:top"><p>10.2%</p></td><td style="vertical-align:top"><p>17.6%</p></td><td style="vertical-align:top"><p>10.6%</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;hours&nbsp;after&nbsp;application</p></td><td style="vertical-align:top"><p>22.8%</p></td><td style="vertical-align:top"><p>8.6%</p></td><td style="vertical-align:top"><p>21.1%</p></td><td style="vertical-align:top"><p>9.9%</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;29&nbsp;p‑value</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>‑</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;3: Percentage of subjects with severe erythema at baseline Day&nbsp;1&nbsp;(CEA or PSA grade&nbsp;4) with&nbsp;2‑grade improvement in both CEA and PSA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Success day&nbsp;29</p></td><td colspan="2" style="vertical-align:top"><p>Study&nbsp;1&nbsp;+ Study&nbsp;2</p></td></tr><tr><td style="vertical-align:top"><p>Mirvaso Gel n=79</p></td><td style="vertical-align:top"><p>Vehicle Gel n=63</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;hours after application</p></td><td style="vertical-align:top"><p>22.8%</p></td><td style="vertical-align:top"><p>9.5%</p></td></tr><tr><td style="vertical-align:top"><p>6&nbsp;hours after application</p></td><td style="vertical-align:top"><p>26.6%</p></td><td style="vertical-align:top"><p>7.9%</p></td></tr><tr><td style="vertical-align:top"><p>9&nbsp;hours after application</p></td><td style="vertical-align:top"><p>20.3%</p></td><td style="vertical-align:top"><p>11.1%</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;hours after application</p></td><td style="vertical-align:top"><p>21.5%</p></td><td style="vertical-align:top"><p>4.8%</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;29&nbsp;p‑value</p></td><td style="vertical-align:top"><p>0.003</p></td><td style="vertical-align:top"><p>‑</p></td></tr></tbody></table><p>&nbsp;</p><p><strong>Table&nbsp;4: Percentage of subjects with a&nbsp;1‑grade improvement in both </strong><strong>CEA and PSA</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2" style="vertical-align:top"><p>Success Day&nbsp;29</p></td><td colspan="2" style="vertical-align:top"><p>Study&nbsp;1</p></td><td colspan="2" style="vertical-align:top"><p>Study&nbsp;2</p></td></tr><tr><td style="vertical-align:top"><p>Mirvaso Gel&nbsp;n=127</p></td><td style="vertical-align:top"><p>Vehicle Gel&nbsp;n=128</p></td><td style="vertical-align:top"><p>Mirvaso Gel&nbsp;n=142</p></td><td style="vertical-align:top"><p>Vehicle Gel&nbsp;n=142</p></td></tr><tr><td style="vertical-align:top"><p>3&nbsp;hours after application</p></td><td style="vertical-align:top"><p>70.9%</p></td><td style="vertical-align:top"><p>32.8%</p></td><td style="vertical-align:top"><p>71.1%</p></td><td style="vertical-align:top"><p>40.1%</p></td></tr><tr><td style="vertical-align:top"><p>6&nbsp;hours after application</p></td><td style="vertical-align:top"><p>69.3%</p></td><td style="vertical-align:top"><p>32.0%</p></td><td style="vertical-align:top"><p>64.8%</p></td><td style="vertical-align:top"><p>43.0%</p></td></tr><tr><td style="vertical-align:top"><p>9&nbsp;hours after application</p></td><td style="vertical-align:top"><p>63.8%</p></td><td style="vertical-align:top"><p>29.7%</p></td><td style="vertical-align:top"><p>66.9%</p></td><td style="vertical-align:top"><p>39.4%</p></td></tr><tr><td style="vertical-align:top"><p>12&nbsp;hours&nbsp;after&nbsp;application</p></td><td style="vertical-align:top"><p>56.7%</p></td><td style="vertical-align:top"><p>30.5%</p></td><td style="vertical-align:top"><p>53.5%</p></td><td style="vertical-align:top"><p>40.1%</p></td></tr><tr><td style="vertical-align:top"><p>Day&nbsp;29&nbsp;p‑value</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>‑</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>‑</p></td></tr></tbody></table><p>&nbsp;</p><p>No clinically meaningful trends with respect to tachyphylaxis or rebound effects (worsening of baseline erythema after cessation of treatment) were observed with use of Mirvaso for&nbsp;29&nbsp;days.</p><p>The results from a long term open label study in&nbsp;449&nbsp;patients, with continuous treatment for up to one year, confirmed that chronic use of Mirvaso is safe and effective. Daily reductions in erythema for the first month of use (as measured with the CEA and PSA scales) were similar to those observed in the controlled trials, and those reductions were achievable for up to&nbsp;12&nbsp;months with no apparent loss of&nbsp;effect over time. The overall frequencies of adverse reactions in this study are reflected in Table&nbsp;1&nbsp;above, with the highest rates occurring in the first&nbsp;29&nbsp;days of use. No adverse reactions had&nbsp;an&nbsp;increase in frequency over time, and there was no evidence that long‑term use of Mirvaso&nbsp;conveyed an increased risk of occurrence of any specific type of adverse reaction.</p><p>Concomitant use of Mirvaso with other medicinal products for the treatment of inflammatory lesions of rosacea has not been systematically investigated. However, in the long term open label study, the efficacy and safety of Mirvaso, as described above, was not affected by the concomitant use of cosmetics or other medicinal products (e.g. topical metronidazole, topical azelaic acid, and oral tetracyclines including low dose doxycycline) for the treatment of inflammatory lesions of rosacea in&nbsp;the concerned subpopulation (131/449&nbsp;patients in the study used concomitant rosacea medicinal product).</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has waived the obligation to submit the results of studies with Mirvaso in all subsets of the paediatric population in treatment of rosacea (see section&nbsp;4.2&nbsp;for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>The absorption of brimonidine from Mirvaso was evaluated in a clinical study in&nbsp;24&nbsp;adult subjects with facial erythema of rosacea. All enrolled subjects received a single‑day ocular administration of a&nbsp;0.2% eye drops solution of brimonidine followed by a once daily cutaneous application of Mirvaso for&nbsp;29&nbsp;days (intra‑individual comparison of systemic exposure). On Day&nbsp;1&nbsp;of the study, all subjects received&nbsp;1&nbsp;drop of the&nbsp;0.2% eye drops solution in each eye, every&nbsp;8&nbsp;hours over a&nbsp;24‑hour period (3&nbsp;doses in total).</p><p>After repeated cutaneous application of Mirvaso on facial skin, no drug accumulation in plasma was observed throughout the treatment duration: the highest mean (&plusmn;&nbsp;standard deviation) plasma maximum concentration (C<sub>max</sub>) and area under the concentration‑time curve from&nbsp;0&nbsp;to&nbsp;24&nbsp;hours (AUC<sub>0‑24hr</sub>) were&nbsp;46&nbsp;&plusmn;&nbsp;62&nbsp;pg/mL and&nbsp;417&nbsp;&plusmn;&nbsp;264&nbsp;pg.hr/mL respectively. These levels are significantly lower (2‑fold) than those observed following single‑day ocular administration of a&nbsp;0.2% eye drops solution of brimonidine.</p><p><u>Distribution</u></p><p>The protein binding of brimonidine has not been studied.</p><p><u>Biotransformation</u></p><p>Brimonidine is extensively metabolised by the liver.</p><p><u>Elimination</u></p><p>Urinary excretion is the major route of elimination of brimonidine and its metabolites.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non‑clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carbomer</p><p>Methylparahydroxybenzoate (E218)</p><p>Phenoxyethanol</p><p>Glycerol</p><p>Titanium dioxide</p><p>Propylene glycol</p><p>Sodium hydroxide</p><p>Purified water</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product does not require any special storage condition.</p><p>Do not freeze.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>[2g]</p><p>Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) closure.</p><p>10&nbsp;g;&nbsp;30g]</p><p>Polyethylene (PE)/Aluminium (Al)/ Polyethylene (PE) laminated plastic tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.</p><p>Or</p><p>[2g]</p><p>Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes with a high density polyethylene (HDPE) head and polyethylene (PE) child resistant closure</p><p>[10&nbsp;g;&nbsp;30g]</p><p>Polyethylene (PE)/Copolymer/Aluminium (Al)/Copolymer/Polyethylene (PE) polyfoil tubes with a high density polyethylene (HDPE) head and polypropylene (PP) child resistant closure.</p><p>Pack sizes:&nbsp;1&nbsp;tube of&nbsp;2&nbsp;g,10&nbsp;g or&nbsp;30&nbsp;g.</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Galderma International
Tour Europlaza, 20 avenue André Prothin – La Défense 4
La Défense Cedex 92927
France
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Dec 2019
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>